Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sino Biopharmaceutical (SMZ1) Stock Price & Analysis

0 Followers

SMZ1 Stock Chart & Stats

CHF 0.57CHF 0.01(-1.55%)
At close: 5:30 PM GMT+1
No data to display
Day’s Range
CHF 0.57 - CHF 0.58
52-Week Range
CHF 0.48 - CHF 0.62
Previous Close
CHF 0.58
Volume
N/A
Average Volume (3M)
0
Market Cap
CHF 10.41B
Enterprise Value
CHF 83.38B
Total Cash (Recent Filing)
CHF 27.58B
Total Debt (Recent Filing)
CHF 17.17B
Price to Earnings (P/E)
36.0
Beta
-0.67
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
0.01
Next Dividend Ex-Date
N/A
Dividend Yield
1.88%

Bulls Say, Bears Say

Bulls Say

Reaccelerating Revenue Growth

Improving top-line growth indicates stronger demand and commercialization across the medicine portfolio after several slower periods. If sustained, this momentum can broaden the revenue base, support operating leverage, and provide resources for continued investment in research, approvals, and market expansion.

Strong Gross Margins

Consistently high gross margins demonstrate substantial economic value in the company’s branded generic and innovative medicine portfolio. This level of product profitability provides a durable buffer for research, regulatory, and commercialization spending while helping preserve operating earnings through changing sales conditions.

Healthy Cash Generation

The rebound in operating and free cash flow strengthens the company’s ability to fund product development, commercialization, and other investments internally. Free cash flow to net income remained about 0.82, supporting the quality of reported earnings and improving financial resilience over the coming quarters.

Bears Say

Falling Net Profitability

The sharp decline in net margin shows that revenue growth is not translating into bottom-line earnings as efficiently as before. Persistent pressure could reduce reinvestment capacity, weaken returns on equity, and make future earnings less predictable even if the company maintains strong gross margins.

Rising Leverage

The year-over-year increase in debt has made the capital structure less conservative while profitability and return on equity have weakened. Higher leverage can reduce financial flexibility, increase the importance of stable earnings, and constrain the company’s ability to fund growth or absorb sustained operating pressure.

Modest Operating Cash Coverage

Although overall cash generation improved, the modest conversion of reported operating profit into operating cash indicates that working capital or non-cash items materially affect cash realization. This can make internally available funding less predictable and complicate planning for sustained investment in the product portfolio.

SMZ1 FAQ

What was Sino Biopharmaceutical’s price range in the past 12 months?
Sino Biopharmaceutical lowest stock price was CHF0.48 and its highest was CHF0.62 in the past 12 months.
What is Sino Biopharmaceutical’s market cap?
Sino Biopharmaceutical’s market cap is CHF10.41B.
When is Sino Biopharmaceutical’s upcoming earnings report date?
Sino Biopharmaceutical’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 140 days.
How were Sino Biopharmaceutical’s earnings last quarter?
Sino Biopharmaceutical released its earnings results on Aug 19, 2026. The company reported CHF0.024 earnings per share for the quarter, beating the consensus estimate of CHF0.015 by CHF0.009.
Is Sino Biopharmaceutical overvalued?
According to Wall Street analysts Sino Biopharmaceutical’s price is currently Undervalued.
Does Sino Biopharmaceutical pay dividends?
Sino Biopharmaceutical does not currently pay dividends.
What is Sino Biopharmaceutical’s EPS estimate?
Sino Biopharmaceutical’s EPS estimate is 0.01.
How many shares outstanding does Sino Biopharmaceutical have?
Sino Biopharmaceutical has 18,682,953,000 shares outstanding.
What happened to Sino Biopharmaceutical’s price movement after its last earnings report?
Sino Biopharmaceutical reported an EPS of CHF0.024 in its last earnings report, beating expectations of CHF0.015. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical?
Currently, no hedge funds are holding shares in CH:SMZ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology